Arakwar

A house door lock isn’t that much about security either.

Unless they sell the new insulin at cost, then no, they don’t get to charge more for the existing product.

They always say that they charge more to pay for the risk from R&D, but having people pay more an existing product to finance future R&D is the complete opposite of that.

This is why some stuff should never be handled by private corporations.